An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia

ABSTRACT: Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in deve...

Full description

Autores:

Buendía Rodrígez, Jefferson Antonio
Vallejos, Carlos
Pichón Rivière, Andrés

Tipo de recurso:

Article of investigation

Fecha de publicación:

2013

Institución:

Universidad de Antioquia

Repositorio:

Repositorio UdeA

Idioma:

eng

OAI Identifier:

oai:bibliotecadigital.udea.edu.co:10495/35721

Acceso en línea:

https://hdl.handle.net/10495/35721

Palabra clave:

Neoplasias de la Mama
Breast Neoplasms
Factor de Crecimiento Epidérmico
Epidermal Growth Factor
Trastuzumab
Antineoplásicos
Antineoplastic Agents
Costo - Efectividad
Cost effectiveness
Colombia
Colombia

Rights

openAccess

License

https://creativecommons.org/licenses/by-nc-nd/4.0/